These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34771631)

  • 1. Factors Associated with Thyroid-Related Adverse Events in Patients Receiving PD-1 or PD-L1 Inhibitors Using Machine Learning Models.
    Kim W; Cho YA; Kim DC; Jo AR; Min KH; Lee KE
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach.
    Heilbroner SP; Few R; Mueller J; Chalwa J; Charest F; Suryadevara S; Kratt C; Gomez-Caminero A; Dreyfus B; Neilan TG
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Machine Learning Approaches for Assessing Risk Factors of Adrenal Insufficiency in Patients Undergoing Immune Checkpoint Inhibitor Therapy.
    Kim W; Cho YA; Min KH; Kim DC; Lee KE
    Pharmaceuticals (Basel); 2023 Aug; 16(8):. PubMed ID: 37631013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with immune-related thyroid dysfunction induced by PD-1/PD-L1 inhibitors in cancer patients: an observational study.
    Wei XC; Guo YY; Zhang Y; Bu YS; Zhang FY
    J Chemother; 2024 Jan; ():1-8. PubMed ID: 38240051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 6. From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer.
    D'Andréa G; Lassalle S; Guevara N; Mograbi B; Hofman P
    Theranostics; 2021; 11(3):1310-1325. PubMed ID: 33391536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
    Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
    Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machine Learning for Predicting Hyperglycemic Cases Induced by PD-1/PD-L1 Inhibitors.
    Yang J; Li N; Lin W; Shi L; Deng M; Tong Q; Yang W
    J Healthc Eng; 2022; 2022():6278854. PubMed ID: 36032541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
    Deng S; Yang Q; Shu X; Lang J; Lu S
    Front Pharmacol; 2019; 10():1063. PubMed ID: 31607917
    [No Abstract]   [Full Text] [Related]  

  • 10. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
    Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
    Front Immunol; 2020; 11():624547. PubMed ID: 33552089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis.
    Tian Y; Li R; Liu Y; Li M; Song Y; Zheng Y; Gao A; Wen Q; Su G; Sun Y
    Front Oncol; 2021; 11():667650. PubMed ID: 34322382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.
    Hall KH; Liu Y; Jiang C; Harvey RD
    Pharmacotherapy; 2020 Feb; 40(2):133-141. PubMed ID: 31863604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.
    Jaafar J; Fernandez E; Alwan H; Philippe J
    Endocr Connect; 2018 May; 7(5):R196-R211. PubMed ID: 29739808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
    Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
    Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer.
    Zhou F; Zhao W; Gong X; Ren S; Su C; Jiang T; Zhou C
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.